FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3007598624> ?p ?o ?g. }

• W3007598624 endingPage "708" @default.
• W3007598624 startingPage "695" @default.
• W3007598624 abstract "Duchenne muscular dystrophy (DMD) is a devastating neuromuscular disease caused by an absence of the dystrophin protein, which is essential for muscle fiber integrity. Among the developed therapeutic strategies for DMD, the exon-skipping approach corrects the frameshift and partially restores dystrophin expression. It could be achieved through the use of antisense sequences, such as peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) or the small nuclear RNA-U7 carried by an adeno-associated virus (AAV) vector. AAV-based gene therapy approaches have potential for use in DMD treatment but are subject to a major limitation: loss of the AAV genome, necessitating readministration of the vector, which is not currently possible, due to the immunogenicity of the capsid. The PPMO approach requires repeated administrations and results in only weak cardiac dystrophin expression. Here, we evaluated a combination of PPMO- and AAV-based therapy in a mouse model of severe DMD. Striking benefits of this combined therapy were observed in striated muscles, with marked improvements in heart and diaphragm structure and function, with unrivalled extent of survival, opening novel therapeutic perspectives for patients. Duchenne muscular dystrophy (DMD) is a devastating neuromuscular disease caused by an absence of the dystrophin protein, which is essential for muscle fiber integrity. Among the developed therapeutic strategies for DMD, the exon-skipping approach corrects the frameshift and partially restores dystrophin expression. It could be achieved through the use of antisense sequences, such as peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) or the small nuclear RNA-U7 carried by an adeno-associated virus (AAV) vector. AAV-based gene therapy approaches have potential for use in DMD treatment but are subject to a major limitation: loss of the AAV genome, necessitating readministration of the vector, which is not currently possible, due to the immunogenicity of the capsid. The PPMO approach requires repeated administrations and results in only weak cardiac dystrophin expression. Here, we evaluated a combination of PPMO- and AAV-based therapy in a mouse model of severe DMD. Striking benefits of this combined therapy were observed in striated muscles, with marked improvements in heart and diaphragm structure and function, with unrivalled extent of survival, opening novel therapeutic perspectives for patients." @default.
• W3007598624 created "2020-03-06" @default.
• W3007598624 creator A5017354720 @default.
• W3007598624 creator A5024052810 @default.
• W3007598624 creator A5035187314 @default.
• W3007598624 creator A5057185431 @default.
• W3007598624 creator A5059739845 @default.
• W3007598624 creator A5064475043 @default.
• W3007598624 creator A5070456505 @default.
• W3007598624 creator A5070566847 @default.
• W3007598624 creator A5078129930 @default.
• W3007598624 creator A5091189518 @default.
• W3007598624 date "2020-06-01" @default.
• W3007598624 modified "2023-10-18" @default.
• W3007598624 title "Combined Treatment with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomer-PPMO and AAV-U7 Rescues the Severe DMD Phenotype in Mice" @default.
• W3007598624 cites W1756023647 @default.
• W3007598624 cites W1997089606 @default.
• W3007598624 cites W2003777088 @default.
• W3007598624 cites W2005245653 @default.
• W3007598624 cites W2007123925 @default.
• W3007598624 cites W2012621742 @default.
• W3007598624 cites W2019563312 @default.
• W3007598624 cites W2027064784 @default.
• W3007598624 cites W2033179276 @default.
• W3007598624 cites W2036143972 @default.
• W3007598624 cites W2038428739 @default.
• W3007598624 cites W2052395573 @default.
• W3007598624 cites W2061596420 @default.
• W3007598624 cites W2062442451 @default.
• W3007598624 cites W2072578275 @default.
• W3007598624 cites W2077301034 @default.
• W3007598624 cites W2081550861 @default.
• W3007598624 cites W2090849645 @default.
• W3007598624 cites W2116279332 @default.
• W3007598624 cites W2116484895 @default.
• W3007598624 cites W2116947711 @default.
• W3007598624 cites W2137542902 @default.
• W3007598624 cites W2142169677 @default.
• W3007598624 cites W2150948543 @default.
• W3007598624 cites W2157112460 @default.
• W3007598624 cites W2179446376 @default.
• W3007598624 cites W2181479067 @default.
• W3007598624 cites W2196662084 @default.
• W3007598624 cites W2423822803 @default.
• W3007598624 cites W2460055212 @default.
• W3007598624 cites W2493461540 @default.
• W3007598624 cites W2588262749 @default.
• W3007598624 cites W2601070131 @default.
• W3007598624 cites W2736939674 @default.
• W3007598624 cites W2765214637 @default.
• W3007598624 cites W2885885948 @default.
• W3007598624 cites W2898775770 @default.
• W3007598624 cites W2907199792 @default.
• W3007598624 cites W2914658811 @default.
• W3007598624 cites W2948019101 @default.
• W3007598624 cites W2955953498 @default.
• W3007598624 cites W2968156885 @default.
• W3007598624 cites W2972931782 @default.
• W3007598624 cites W2995639049 @default.
• W3007598624 cites W3001754284 @default.
• W3007598624 cites W35167305 @default.
• W3007598624 doi "https://doi.org/10.1016/j.omtm.2020.03.011" @default.
• W3007598624 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7177166" @default.
• W3007598624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32346547" @default.
• W3007598624 hasPublicationYear "2020" @default.
• W3007598624 type Work @default.
• W3007598624 sameAs 3007598624 @default.
• W3007598624 citedByCount "13" @default.
• W3007598624 countsByYear W30075986242020 @default.
• W3007598624 countsByYear W30075986242021 @default.
• W3007598624 countsByYear W30075986242022 @default.
• W3007598624 countsByYear W30075986242023 @default.
• W3007598624 crossrefType "journal-article" @default.
• W3007598624 hasAuthorship W3007598624A5017354720 @default.
• W3007598624 hasAuthorship W3007598624A5024052810 @default.
• W3007598624 hasAuthorship W3007598624A5035187314 @default.
• W3007598624 hasAuthorship W3007598624A5057185431 @default.
• W3007598624 hasAuthorship W3007598624A5059739845 @default.
• W3007598624 hasAuthorship W3007598624A5064475043 @default.
• W3007598624 hasAuthorship W3007598624A5070456505 @default.
• W3007598624 hasAuthorship W3007598624A5070566847 @default.
• W3007598624 hasAuthorship W3007598624A5078129930 @default.
• W3007598624 hasAuthorship W3007598624A5091189518 @default.
• W3007598624 hasBestOaLocation W30075986241 @default.
• W3007598624 hasConcept C104317684 @default.
• W3007598624 hasConcept C126322002 @default.
• W3007598624 hasConcept C136571751 @default.
• W3007598624 hasConcept C173396325 @default.
• W3007598624 hasConcept C194583182 @default.
• W3007598624 hasConcept C2778776201 @default.
• W3007598624 hasConcept C2778943923 @default.
• W3007598624 hasConcept C2780394045 @default.
• W3007598624 hasConcept C36823959 @default.
• W3007598624 hasConcept C502942594 @default.
• W3007598624 hasConcept C54355233 @default.
• W3007598624 hasConcept C71924100 @default.
• W3007598624 hasConcept C86803240 @default.
• W3007598624 hasConceptScore W3007598624C104317684 @default.

• next